FBR & Co reissued their outperform rating on shares of Prima BioMed Ltd. (NASDAQ:PBMD) in a report issued on Friday. The firm currently has a $6.00 price target on the stock.
Immutep Ltd. buy Quitte
Start price
21.07.16
/
50%
€0.15
Target price
23.01.17
€0.20
Performance (%)
-13.33%
End price
23.01.17
€0.13
Summary
This prediction ended on 23.01.17 with a price of €0.13. The prediction for Immutep Ltd. disappointed with a performance of -13.33%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immutep Ltd. | 0.000% | 0.000% | -80.970% | -86.649% |
| iShares Core DAX® | 2,99 % | 3,22 % | 4,27 % | 53,70 % |
| iShares Nasdaq 100 | -1,58 % | -3,17 % | 24,75 % | 76,70 % |
| iShares Nikkei 225® | -2,25 % | -9,92 % | 43,52 % | 60,79 % |
| iShares S&P 500 | -0,01 % | 1,64 % | 20,97 % | 62,81 % |
Comments by Quitte for this prediction
In the thread Immutep Ltd. diskutieren
wer wagt ....
(Laufzeit überschritten)